Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization

Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization

Immune checkpoint inhibitors, combined with anti-angiogenic agents or locoregional treatments (e.g., transarterial chemoembolization (TACE)), are expected to become standard-of-care for unresectable hepatocellular carcinoma (HCC). We measured the plasma levels of 16 soluble checkpoint proteins using...

Full description

Bibliographic Details
Main Authors: Naoshi Odagiri, Hoang Hai, Le Thi Thanh Thuy, Minh Phuong Dong, Maito Suoh, Kohei Kotani, Atsushi Hagihara, Sawako Uchida-Kobayashi, Akihiro Tamori, Masaru Enomoto, Norifumi Kawada
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cancers
Subjects:
HCC
liver cancer
molecular-targeted agent
TACE
tyrosine kinase inhibitor
Online Access:https://www.mdpi.com/2072-6694/12/8/2045

Internet

https://www.mdpi.com/2072-6694/12/8/2045

Similar Items